Accessibility Menu
Vericel logo

Vericel(NASDAQ) VCEL

Current Price$45.74
Market Cap$2.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1997)-96%
5 Year-15%
1 Year+13%
1 Month+8%
Vericel last closing stock price
MetricPriceDate
Last closeUSD 45.052026-07-24
Vericel stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.41%USD 46.642026-07-17
1 month+8.06%USD 41.692026-06-24
3 month+26.4%USD 35.642026-04-24
Year to date+25.1%USD 36.012025-12-31
1 year+13.42%USD 39.722025-07-24
3 year+20.45%USD 37.402023-07-25
5 year-15.38%USD 53.242021-07-23
Since inception-95.98%USD 1,120.001997-02-04

Vericel Financials at a Glance

Market Cap

$2.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$292.09M

Net Income (TTM)

$21.46M

EPS (TTM)

$0.41

P/E Ratio

110.15

Dividend

$0.00

Beta (Volatility)

1.44 (Average)

Price

$45.74

Volume

1,917

Open

$45.61

Previous Close

$45.05

Daily Range

$45.24 - $46.11

52-Week Range

$28.95 - $48.75

Estimated Earnings Date

Jul 30, 2026

VCEL News

SellAlert-Red.png

Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests

Jonathan PoncianoJun 27, 2026
f5acfa2370b69ef05efd688fbbc9e56e546c0092-1401x1251.png

Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More

Jonathan PoncianoMay 30, 2026
GettyImages-1250270666.jpg

Brown Capital Discloses $31 Million Sale of Vericel Stock as Small-Cap Biotech Reports Earnings

Jonathan PoncianoNov 6, 2025
Foolcom-Featured.png

Vericel Q2 Revenue Jumps 20%

Motley Fool Markets TeamAug 5, 2025

Why Vericel Tumbled by Nearly 15% on Tuesday

Eric VolkmanJun 29, 2021
GettyImages-1281616591

Why Vericel Stock Raced 13% Higher on Thursday

Eric VolkmanMar 18, 2021
GettyImages-1175270464

2 Overvalued Biotech Stocks Still Worth Buying

Alex CarchidiMar 4, 2021
rising_stock_chart_lcd_screen

Why Vericel Stock Is Soaring Today

Brian FeroldiNov 5, 2019
Page 1

VCEL: Motley Fool Moneyball Superscore

76

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vericel

Vericel helps people heal from severe knee and burn injuries. The company uses a patient's own cells to repair damaged tissue. These advanced therapies aim to restore health and movement.

What Does Vericel Make?

  • Knee Cartilage Repair: MACI uses a patient's own cells to fix knee defects; it uses tissue engineering to grow new cartilage.
  • Arthroscopic Tools: MACI Arthro lets surgeons perform repairs through small incisions using specialized instruments.
  • Skin Replacement: Epicel provides permanent skin for patients with life-threatening burns covering 30% or more of their body.
  • Burn Treatment: NexoBrid removes eschar, which is damaged tissue, from severe thermal burns in adults and children.

Building for the Future

  • Launched MACI Arthro in the third quarter of 2024 following approval from the Food and Drug Administration.
  • Began the MASCOT clinical trial in late 2025 to study using cell therapy for ankle cartilage repair.
  • Leased a 126,000 square foot facility in Burlington to increase production capacity for its main products.
  • Secured an exclusive license for NexoBrid from MediWound Ltd to treat burn patients in North America.
  • Expanded the MACI sales team by approximately 30% in late 2025 to reach more surgeons.

Specialized Care for Severe Injuries

Vericel is a leader in tissue engineering with products that use a patient's own biology to heal. The company maintains its own manufacturing facilities to ensure quality and meet growing demand for its therapies.

Financial Performance

  • Revenue grew to $92.9 million in Q4 2025, up 23% from Q4 2024.
  • Gross profit reached $73.1 million in Q4 2025, a 25% year-over-year increase.
  • Net income was $23.2 million in Q4 2025, up 17% from the prior year.
  • Operating cash flow fell to $15 million in Q4 2025, down 32% from Q4 2024.

Bottom Line

Vericel has evolved from a developmental biotech into a profitable commercial leader in regenerative medicine. It continues to grow by developing less invasive surgical techniques and expanding into new medical markets.

AI Generated • Apr 29, 2026

Industry

Biotechnology

Sector

Health Care

Employees

398

CEO

Dominick C. Colangelo

Website

www.vcel.com

Headquarters

Cambridge, MA 02139, US

VCEL Financials

Key Financial Metrics (TTM)

Gross Margin

74.84%

Operating Margin

5.40%

Net Income Margin

7.35%

Return on Equity

6.41%

Return on Capital

2.44%

Return on Assets

4.42%

Earnings Yield

0.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

51.07M

Volume

1.92K

Avg. Volume

646.36K

Financials (TTM)

Gross Profit

$218.59M

Operating Income

$15.77M

EBITDA

$35.26M

Operating Cash Flow

$61.69M

Capital Expenditure

-$3.89M

Free Cash Flow

$57.81M

Cash & ST Invst.

$145.34M

Total Debt

$94.54M

Vericel Performance Analysis

Vericel annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 164,365,0005.2%
20232023-12-31USD 197,516,00020.2%
20242024-12-31USD 237,224,00020.1%
20252025-12-31USD 276,259,00016.5%
Vericel sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3020.2%
Q32025-09-306.7%
Q42025-12-3137.7%
Q12026-03-31-26.4%
Vericel annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.35120.5%
20232023-12-31USD -0.07-81.1%
20242024-12-31USD 0.20N/A
20252025-12-31USD 0.3258.0%
Vericel sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3095.2%
Q32025-09-30989.1%
Q42025-12-31360.1%
Q12026-03-31-126.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$68.43M

+30.1%

Gross Profit

$49.27M

+35.8%

Gross Margin

72.00%

N/A

Market Cap

$2.30BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.78M

N/A

Employees

398

N/A

Net Income

-$6.30M

+44.0%

EBITDA

-$2.88M

+65.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$145.34M

+28.7%

Total Debt

$94.54M

-4.5%

Accounts Receivable

$72.38M

+36.8%

Inventory

$18.35M

+7.3%

Long Term Debt

$80.36M

-8.5%

Short Term Debt

$14.18M

+27.0%

Return on Assets

4.42%

N/A

Return on Invested Capital

3.60%

N/A

Free Cash Flow

$15.13M

+298.7%

Operating Cash Flow

$16.38M

+148.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NUVBNuvation Bio Inc.
$6.60+2.73%
HRMYHarmony Biosciences Holdings, Inc.
$36.08+2.15%
AUPHAurinia Pharmaceuticals Inc.
$15.39+0.26%
QUREuniQure N.V.
$38.65-0.82%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.20+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.25-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$45.36+0.01%
BMNRBitmine Immersion Technologies
$17.82+0.13%

Questions About VCEL

What is the current price of Vericel?

Vericel is trading at $45.74 per share.

What is the 52-week range for Vericel?

Over the past 52 weeks, Vericel has traded between $28.95 and $48.75.

How much debt does Vericel have?

As of the most recent reporting period, Vericel reported total debt of $96.42M.

How much cash does Vericel have on hand?

Vericel reported $109.30M in cash and cash equivalents in its most recent financial results.

What is Vericel’s dividend yield?

Vericel does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services